remdesivir

Merdad Parsey on building a case for remdesivir amid the coronavirus pandemic

Gilead's Chief Medical Officer talks about the challenges of clinical design in the time of COVID-19




remdesivir

Scaling up remdesivir amid the coronavirus crisis

Manufacturing experts weigh in on Gilead's challenge in making its potential COVID-19 treatment




remdesivir

Scaling up remdesivir amid the coronavirus crisis

Manufacturing experts weigh in on Gilead's challenge in making its potential COVID-19 treatment




remdesivir

Gilead's remdesivir gets emergency use authorization based on preliminary data in COVID-19

Limited results from a NIAID study suggest the drug helps people with COVID-19 recover faster




remdesivir

[ASAP] Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

ACS Central Science
DOI: 10.1021/acscentsci.0c00489




remdesivir

Treatment with remdesivir did not speed up recovery or reduce deaths from COVID-19: Lancet




remdesivir

50% of Covid-19 patients treated with Remdesivir showed positive results: US team




remdesivir

US allows emergency use of remdesivir for Covid-19 patients




remdesivir

Gilead announces global remdesivir licensing plan even as patents hit rough waters in India

Gilead said it was in discussions with 'some of the world’s leading chemical and pharmaceutical manufacturing companies' to produce remdesivir for Europe, Asia and the developing world through at least 2022